Trong et al reported the RENEG model for evaluating a patient with a non-enhancing glioma. While non-enhancing gliomas are often benign, some may show clinically aggressive behavior. The authors are from Heidelberg University and the German Cancer Research Center.
RENEG is an acronym for risk estimation of non-enhancing glioma.
Patient selection: non-enhancing glioma
Outcome: clinically aggressive (malignant) glioma such as glioblastoma or WHO grade 4 astrocytoma
Parameters:
(1) supraventricular zone (SVZ) involvement
(2) T2 to FLAIR mismatch (a complete or near complete hyperintense T2 sign and relatively hypointense signal on FLAIR sequences
(3) age in years
Parameter
Finding
Points
SVZ involvement
no
0
yes
0.165
T2 to FLAIR mismatch
no
0
yes
-2.247
age
0.089 * (age)
value of X =
= SUM(points for all of the parameters) - 3.727
probability of an aggressive glioma =
= 1 / (1 + EXP((-1) * X))
Performance:
• The area under the ROC curve is 0.89.
To read more or access our algorithms and calculators, please log in or register.
